Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562443 · ClinicalTrials.gov registry record · Phase 3
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
A Phase 3 study, sponsored by Traws Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT02562443 is a Phase 3 study that was terminated before completion, run by Traws Pharma. The registered enrollment target is 372 participants.
The verdict
NCT02562443, a Phase 3 study, was terminated before completion, sponsored by Traws Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
Interventions
- DRUG rigosertib
- DRUG Any approved or standard-of-care therapy
- DRUG best supportive care (BSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2015-12-02 |
| Est. Completion | 2021-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02562443
The ClinicalTrials.gov registry entry for NCT02562443 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rigosertib is the first listed.
NCT02562443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02562443 about?
NCT02562443 is a clinical study titled "Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA". The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients wit...
What is the current status of trial NCT02562443?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2015-12-02. Estimated completion is 2021-07-26.
What interventions are being tested in trial NCT02562443?
The interventions under investigation include: rigosertib (DRUG), Any approved or standard-of-care therapy (DRUG), best supportive care (BSC) (DRUG).
Who is sponsoring clinical trial NCT02562443?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.